Pfizer Inc.

NYSE:PFE   3:59:59 PM EDT
+0.26 (+0.51%)
4:30:47 PM EDT: $50.62 -0.04 (-0.07%)

Shanghai Fosun Pharma Says Unit Entered Sub-License Agreement With Medicines Patent Pool

Published: 03/18/2022 04:21 GMT
Pfizer Inc. (PFE) - Notes Recent Media Reports That Mpp Has Sublicensed 35 Cos to Manufacture Generic Version of Pfizer's Oral Covid-19 Treatment .
Unit Recently Entered Sub-license Agreement With Medicines Patent Pool.
Deal Concerns Sublicensing by Mpp in Favour of Unit to Produce Active Pharmaceutical Ingredient and Finished Drug for Nirmatrelvir.
Mpp Has Granted Unit to Non-exclusive Sub-license for Manufacturing of Drug and Licensed Product and Related Rights.
Sublicense is Royalty-free for Sales During Period Where Who Has Declared Covid-19 a Public Health Emergency.
Expected Price of Licensed Product Under Such Sub-license Will Be Lower Than Those Supplied to Mid- and High-income Countries.
Deal Concerns Sublicensing by Mpp to Make Generic Version of Licensed Package of Finished Drug Co-administered With Ritonavir for Covid.
Unit Has Not Commenced Manufacturing Or Received Purchase Order for It.
Sales in Low-income Countries Will Remain Royalty Free.